DJ Regeneron's COVID-19 Antibody Drug Generated $145 Million In Sales In Q4 -- MarketWatch
Shares of Regeneron Pharmaceuticals Inc. (REGN) gained 3.2% in premarket trading on Friday after the company said its COVID-19 antibody cocktail treatment generated $145.5 million in sales in the fourth quarter of 2020 as part of its earnings (http://www.marketwatch.com/story/regenerons-stock-rallies-after-profit-rises-well-above-expectations-while-revenue-matches-2021-02-05). The treatment, which received emergency use authorization in the U.S. in November, generated $185.7 million in sales for the full year. The U.S. government has agreed to buy up to about 1.5 million doses of the therapy, a purchase that brings in roughly $2.6 billion in revenue for Regeneron, the company said Friday. Regeneron's stock has rallied 34.0% over the past 12 months, while the broader S&P 500 is up 17.4%.
(END) Dow Jones Newswires
February 05, 2021 07:55 ET (12:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.